# US 2021/0228500 A1 · Cellular retinoid binding protein antagonists and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0228500 A1
- Document ID: US20210228500A1
- Status: Published application
- Kind: A1
- Application number: 15/734,781
- Filed: 2019-06-07
- Published: 2021-07-29
- Earliest claimed: 2018-06-07
- Assignees: Case Western Resrve University
- Applicants: Case Western Resrve University
- Inventors: Marcin Bernard GOLCZAK; Josie Ann SILVAROLI
- Web page: https://patentgrep.com/patent/US20210228500A1

## CPC

- A61K 31/05: Phenols {(cannabinoids A61K31/658)}
- A61P 27/02: Ophthalmic agents
- C07C 39/23: polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
- C07B 2200/07: Optical isomers
- C07C 2601/16: the ring being unsaturated
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A method of treating an ocular, inflammatory, immune, and/or metabolic disorder in a subject in need thereof includes administering to the subject a therapeutically effective amount of a compound having a structure of formula (I).

## Claims

### Claim at position 1

1: A method of treating light induced retinal degeneration in a subject in need thereof, the method comprising:
administering to the subject a therapeutically effective amount of a compound having a structure of formula (II):
or a pharmaceutically acceptable salt, tautomer, or solvate thereof, wherein:
R1 and R2 are each independently H, halogen, alkyl, alkylene-alkoxy, hydroxyl, —C(O)-alkyl, or —C(O)O-alkyl, each of which is optionally substituted with R8;
R3 is alkyl, alkylene, or OH, each of which is optionally substituted with R8;
R5 and R6 are each independently hydroxyl, carboxyl, —C(O)-alkyl, —C(O)O-alkyl, alkylene-C(O)-alkyl, alkylene-C(O)O-alkyl, N(R9)2, alkylene-NH2 alkylene-N(R9)2 or —N(R9)(alkylene-OH), each of which is optionally substituted with R8;
R8 is halogen, alkyl, haloalkyl, alkoxy, or haloalkoxy;
R9 is H, halogen, alkyl, haloalkyl, alkoxy, or haloalkoxy;
R10 is H, halogen, hydroxyl, carboxyl, —C(O)-alkyl, —C(O)O-alkyl, alkylene-C(O)-alkyl, alkylene-C(O)O-alkyl, N(R9)2 alkylene-NH2 alkylene-N(R9)2, or —N(R9)(alkylene-OH), each of which is optionally substituted with R8; and
X1 is NH, O, or CH2
X2, X3, X4, X5 are independently NH, O, CH2 or absent;
Y1 is N or CH; and
the dashed line is an optional bond.

### Claim at position 2

2-9: (canceled)

### Claim at position 3 (depends on 1)

10: The method of claim 1, wherein R1 is H, C1-C6 alkyl, or C1-C6 haloalkyl.

### Claim at position 4 (depends on 1)

11: The method of claim 1, wherein R2 is C1-C6 alkyl, or C1-C6 haloalkyl.

### Claim at position 5 (depends on 1)

12: The method of claim 1, wherein R3 is methyl, ethyl, propyl, methylene, ethylene, propylene, or OH.

### Claim at position 6 (depends on 1)

13: The method of claim 1, wherein R4 is H, methyl, ethyl, or propyl.

### Claim at position 7 (depends on 1)

14: The method of claim 1, wherein R5 and R6 are each independently hydroxyl, carboxyl, —C(O)-alkyl, —C(O)O-alkyl, alkylene-C(O)-alkyl, alkylene-C(O)O-alkyl, or N(R9)2.

### Claim at position 8

15: (canceled)

### Claim at position 9 (depends on 1)

16: The method of claim 1, wherein the compound has a structure of formula (IV):

### Claim at position 10 (depends on 1)

17: The method of claim 1, wherein the compound has a structure of formula (IV):

### Claim at position 11 (depends on 1)

18: The method of claim 1, wherein the compound does not have a structure of formula (IV) or formula (V):

### Claim at position 12 (depends on 1)

19: The method of claim 1, wherein the compound does not produce psychoactive effects in the subject.

### Claim at position 13 (depends on 1)

20: The method of claim 1, wherein the compound does not bind to and/or interact with cannabinoid receptor 1 and/or 2.

### Claim at position 14 (depends on 1)

21: The method of claim 1, wherein the compound is an antagonist of cellular retinol binding protein 1 (CRBP1).

### Claim at position 15 (depends on 1)

22: The method of claim 1, wherein the compound does not inhibit enzymatic activities of enzymes involved in the regeneration of visual chromophores.

### Claim at position 16 (depends on 1)

23: The method of claim 1, wherein the compound does not inhibit enzymatic activities of enzymes involved in the production of retinoic acid or its geometric isomers.

### Claim at position 17 (depends on 1)

24: The method of claim 1, wherein the compound lowers the concentration of retinaldehyde in retinal tissues.

### Claim at position 18 (depends on 1)

25: The method of claim 1, wherein the compound reduces the formation of A2E and/or retinal dimer in the subject's retina.

### Claim at position 19

26-77: (canceled)
